Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips

ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.

Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Boston Scientific (BSX) Earnings Transcript

Image source: The Motley Fool.DATEWednesday, February 4, 2026, 8 a.m. ETCALL PARTICIPANTSChairman and Chief Executive Officer — Michael F. MahoneyExecutive Vice President and Chief Financial Officer — Jonathan MonsonChief Medical Officer — Kenneth SteinVice President, Investor Relations — Lauren TenglerTAKEAWAYSTotal Sales -- Operational revenue reached $5.286 billion for the quarter and $20.74 billion for the year, reflecting 14% and 19% operational growth, respectively.Organic Revenue Gro...

Stocks Slide on CPI, Traders Boost June Fed Rate-Cut Odds | The Close 1/13/2026

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Todays guests are Former Boston Fed President Eric Rosengren, U.S. Bancorp’s Stephen Philipson, BNY Mellon’s Dermot McDonogh, Inflation Insights’ Omair Sharif, Teva Pharmaceutical’s Richard Francis, Gabelli’s Macrae Sykes, AstraZeneca’s Aradhana Sarin, Novo Nordisk’s Mike Doustdar, Illumina’s Jacob Thaysen, Former Kansas City Fed President Th...

Illuminas New Connected Multiomics Platform Set to Boost Its Stock

ILMNs Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.

Illumina Aktie: Comeback in Sicht? 2026 könnte überraschen!

New York (www.aktiencheck.de) - Illumina-Aktienanalyse von TD Cowen:TD Cowen habe das Kursziel für die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) von 115 auf 140 USD erhöht und das "hold"-Rating bestätigt. Die Anpassung sei im Rahmen eines Q4-Ausblicks für den Bereich Life-Science-Tools erfolgt. [mehr]

Illumina Aktie: AXELIOS mit Roche als Gamechanger - Kursziel steigt auf 130 USD

Bad Marienberg (www.aktiencheck.de) - Illumina-Aktienanalyse von Canaccord: Kursziel 130 USD rückt strategische Weichen für 2026Die Illumina-Aktienanalyse von Canaccord sorgt kurz vor dem Jahreswechsel für neue Aufmerksamkeit im Life-Science-Sektor. Canaccord-Analyst Kyle Mikson hat am 22. Dezember 2025 das Kursziel für Illumina deutlich von 112 USD auf 130 USD angehoben und gleichzeitig am Rating "hold" festgehalten. [mehr]

PCCA Partners with Pillumina® to Advance Environmental Sustainability in Compounding with Aluminum Pill Bottles

Houston, TX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PCCA today announced a new collaboration with?Pillumina®,?an innovator in sustainable pharmacy packaging, to bring the first aluminum pill bottle designed for pharmacies to its compounding members. Through this collaboration, PCCA provides its compounding pharmacy members and customers with a durable, fully recyclable alternative to traditional plastic pill bottles and caps. 

Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties

Illumina, Commercial Metals and Newmont have all seen broker upgrades, signaling bullish momentum amid market uncertainties.

Pivotal-Point Nachverfolgung Illumina (ILMN): Genomik-Pionier übertrifft in Q3 mit 1,34 USD die EPS-Prognose und setzt auf Proteomik!

Illumina ist ein weltweit führender Anbieter von Systemen zur Genomsequenzierung und Array-Technologie. Die Produkte des Unternehmens werden in Forschung und Diagnostik zur Analyse genetischer Informationen...

Illumina - Steigende Behandlungszahlen schieben Ergebnis weiter an!

Geschäftstreiber: Der Gensequenzierungsspezialist Illumina (ILMN) hat sich als einer der technologisch führenden Player in diesem Wachstumsmarkt etabliert. Mit Hilfe der von Illumina angebotenen Systeme...

Hopeful Well Find Long-term Solution On China: Illumina CEO

Illumina reported revenue growth and raised its financial guidance for the second straight quarter. Illumina CEO Jacob Thaysen acknowledged the ongoing challenges from US–China export restrictions but said Illumina remains committed to the market while maintaining strong performance globally. He discussed the outlook on "Bloomberg Markets" with Scarlet Fu and Bloomberg The Close’s co-anchor Katie Greifeld. (Source: Bloomberg)

Compared to Estimates, Illumina (ILMN) Q3 Earnings: A Look at Key Metrics

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Illumina Aktie: Stimmung hellt sich auf - reicht das für ein Comeback?

London (www.aktiencheck.de) - Illumina-Aktienanalyse von Barclays:Die Analysten von Barclays haben das Kursziel für die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) von 90 USD auf 95 USD angehoben, bestätigen jedoch das Rating "underweight".Im Rahmen eines Q3-Ausblicks auf den Bereich Life-Science-Tools und Diagnostik hätten die Analysten betont, dass die Endmärkte der Branche aktuell stabil erschienen und künftig mit Verbesserungen zu re...

TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now?

As precision oncology advances, Tempus and Illumina lead the way with innovation. Which stock shows stronger growth momentum now?

Illumina Stock May Benefit From New Agreement to Acquire SomaLogic

ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.

Standard BioTools stock soars after selling SomaLogic to Illumina for $425M By Investing.com

Standard BioTools stock soars after selling SomaLogic to Illumina for $425M

Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software

ILMNs latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.

illumin Holdings Inc. Announces Date for First Quarter 2025 Financial and Operating Results

TORONTO and NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM, OTCQB: ILLMF) (“illumin” or “Company”), a leader in digital advertising technology that empowers marketers to make smarter decisions about communicating with online consumers, announces that it will report its first quarter 2025 financial results before market open on Friday, May 9, 2025.

Resmed Names Salli Schwartz as Chief Investor Relations Officer

Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community

Illumina Aktie: Harter Brocken zu erwarten?

Illumina verzeichnet deutliche Kursverluste, während Analysten gespaltene Meinungen zur Zukunft des Genforschungsspezialisten haben. Entscheidende Quartalszahlen stehen bevor. Die Illumina-Aktie se...

Got $3,000? 2 Artificial Intelligence (AI) Stocks to Buy and Hold for the Long Term

Its hard to watch the value of your investments falter in a short period, but everyone is in the same boat. The good news is that market declines are historically excellent buying opportunities. Markets can fall but they inevitably hit bottom and skyrocket back to new highs over time, providing handsome gains for investors who ride through the volatility. If youve got $3,000 you dont need for other life priorities like reducing debt, this is a great opportunity to invest in competitively posi...

Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders

Keith Meister, Corvex Managements chief investment officer, will join Illuminas board starting March 28. Hes no stranger to the world of biotech.

Illumina Aktie: Neuer Vorstand, alte Herausforderungen

Charlotte (www.aktiencheck.de) - Illumina-Aktienanalyse von BofA Securities: Rating und Kursziel Bank of America bewertet die Aktie von Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) mit "underperform" ein. Das Kursziel laute 90 USD. Trotz zahlreicher personeller Veränderungen sieht das Analysehaus keine grundlegende Änderung der Lage des Unternehmens. [mehr]

Illumina shares rise on WSJ report activist investor Meister will join board By Investing.com

Illumina shares rise on WSJ report activist investor Meister will join board

Activist investor Keith Meister to join Illumina’s board, WSJ reports By Reuters

Activist investor Keith Meister to join Illumina’s board, WSJ reports

Activist investor Keith Meister to join Illuminas board, WSJ reports

Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Illuminas AGD Project Completes 250,000 Whole Genomes: Stock to Gain?

ILMN-NashBios AGD initiative achieves the milestone of completing 250,000 whole genomes.

Illumina Aktie: China-Risiken abgebaut, aber neue Herausforderungen in Sicht?

London (www.aktiencheck.de) - Illumina-Aktienanalyse von Barclays: Aktuelle Bewertung Die Analysten von Barclays bestätigen ihr "underweight"-Rating für Illumina Inc. (ISIN: US4523271090, WKN: 927079, Ticker-Symbol: ILU, NASDAQ-Symbol: ILMN) mit einem Kursziel von 100 USD. Während die gesenkte Guidance für 2025 keine große Überraschung war, bleiben Risiken für das Unternehmen bestehen, insbesondere in den Bereichen genomische Forschung und Agrigenomik. [mehr]